These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18096566)

  • 1. The impact of a false-positive MRI on the choice for mastectomy in BRCA mutation carriers is limited.
    Hoogerbrugge N; Kamm YJ; Bult P; Landsbergen KM; Bongers EM; Brunner HG; Bonenkamp HJ; de Hullu JA; Ligtenberg MJ; Boetes C
    Ann Oncol; 2008 Apr; 19(4):655-9. PubMed ID: 18096566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA;
    Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.
    Murakami W; Tozaki M; Nakamura S; Ide Y; Inuzuka M; Hirota Y; Murakami K; Takahama N; Ohgiya Y; Gokan T
    Breast Cancer; 2019 Sep; 26(5):552-561. PubMed ID: 30820924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
    Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA;
    Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rate of contralateral prophylactic mastectomy is influenced by preoperative MRI recommendations.
    Xia C; Schroeder MC; Weigel RJ; Sugg SL; Thomas A
    Ann Surg Oncol; 2014 Dec; 21(13):4133-8. PubMed ID: 24934585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
    Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Seynaeve C; van Geel AN; Tilanus MM; Bartels CC; Verhoog LC; Brekelmans CT; Burger CW; Niermeijer MF
    Breast Cancer Res Treat; 2002 May; 73(2):97-112. PubMed ID: 12088120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
    Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
    JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.
    Calderon-Margalit R; Paltiel O
    Int J Cancer; 2004 Nov; 112(3):357-64. PubMed ID: 15382059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of interval breast malignancies in patients with BRCA mutations.
    Komenaka IK; Ditkoff BA; Joseph KA; Russo D; Gorroochurn P; Ward M; Horowitz E; El-Tamer MB; Schnabel FR
    Cancer; 2004 May; 100(10):2079-83. PubMed ID: 15139048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence.
    Shah P; Rosen M; Stopfer J; Siegfried J; Kaltman R; Mason B; Armstrong K; Nathanson KL; Schnall M; Domchek SM
    Breast Cancer Res Treat; 2009 Dec; 118(3):539-46. PubMed ID: 19609668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
    Johns D; Agarwal J; Anderson L; Ying J; Kohlmann W
    J Womens Health (Larchmt); 2017 Jun; 26(6):702-706. PubMed ID: 27922795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years.
    Landsbergen KM; Prins JB; Kamm YJ; Brunner HG; Hoogerbrugge N
    Fam Cancer; 2010 Jun; 9(2):213-20. PubMed ID: 19967456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Honing the health message on BRCA mutations.
    Schmidt C
    J Natl Cancer Inst; 2013 Dec; 105(24):1843-4. PubMed ID: 24316597
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
    van Zelst JCM; Mus RDM; Woldringh G; Rutten MJCM; Bult P; Vreemann S; de Jong M; Karssemeijer N; Hoogerbrugge N; Mann RM
    Radiology; 2017 Nov; 285(2):376-388. PubMed ID: 28609204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum of histopathologic findings in risk-reducing bilateral prophylactic mastectomy in patients with and without BRCA mutations.
    Boyraz B; Ly A
    Hum Pathol; 2024 Sep; 151():105534. PubMed ID: 38000681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contralateral Prophylactic Mastectomy Overtreatment: Expectations from Personal Genomics for Tailored Breast Cancer Surgery.
    Zografos GC; Roukos DH
    Ann Surg Oncol; 2010 Mar; 17(3):939; author reply 940. PubMed ID: 19937131
    [No Abstract]   [Full Text] [Related]  

  • 20. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI.
    Vreemann S; van Zelst JCM; Schlooz-Vries M; Bult P; Hoogerbrugge N; Karssemeijer N; Gubern-Mérida A; Mann RM
    Breast Cancer Res; 2018 Aug; 20(1):84. PubMed ID: 30075794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.